Latest News & Features
Americas
Success in complex pharmaceutical litigation often comes down to early preparation and cross-functional alignment. This session explores how companies can proactively manage Hatch-Waxman and BPCIA disputes through strategic front-end planning and operational execution. 19 May 2026
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/39e3d750-52d9-11f1-aebf-970e2643ddeb-Orrick%20Paris%20Group%20300ppi%20(1).webp)
Europe
A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions. 18 May 2026
Americas
A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival. 18 May 2026
Europe
Are the EPO and the UPC diverging in their assessment of inventive step? By analysing key recent pharmaceutical decisions, this presentation highlights potential differences in standards and considers how they impact European patent strategies. 18 May 2026
Americas
The intersection of regulatory strategy and intellectual property protection has become critical to maintaining market exclusivity. This panel examines how life sciences companies can adapt their IP strategies in response to shifting FDA guidance, biosimilar challenges, and evolving agency priorities. 17 May 2026
Americas
As antibodies cement their status as a major therapeutic class, securing robust IP protection has grown increasingly difficult. With heightened scrutiny on enablement and written description requirements, this panel unpacks strategies for building resilient antibody portfolios in a challenging global landscape. 16 May 2026
Unified Patent Court
Understanding the economic mechanisms and cross-border interactions of the UPC is crucial for modern patent litigation. This session untangles the complexities of evidence gathering and cost security, highlighting the critical interplay between European proceedings and US patent strategies. 15 May 2026
Americas
Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets. 14 May 2026
Careers
The biotechnology and life sciences specialist joins from McDonnell Boehnen Hulbert & Berghoff, marking the fifth senior IP hire at the firm this year. 14 May 2026
Americas
The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others. 14 May 2026